CIOMS FORM

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH Day	Month	Year	2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET Day	Month	Year
PRIVACY	DOMINICAN REPUBLIC		PRIVACY		Unk	Male	Unk		Unk	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
DEATH [Death]	TAGRISSO	Yes	No	Not Applicable	Not Related

(Continued on Additional Information Page)

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☒ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING
- ☐ CONGENITAL ANOMALY
- ☐ OTHER

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) TAGRISSO (OSIMERTINIB) Tablet

15. DAILY DOSE(S)
#1) 80 milligram, qd

16. ROUTE(S) OF ADMINISTRATION
#1) Oral use

17. INDICATION(S) FOR USE
#1) LUNG CANCER (Lung cancer)

18. THERAPY DATES(from/to)
#1) Unknown

19. THERAPY DURATION
#1) Unknown

20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☐ NA

21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☒ NA

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Indication	Lung cancer (Lung cancer)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
AstraZeneca
Serban Ghiorghiu
1 Medimmune Way
Gaithersburg, Maryland 20878 UNITED STATES
Phone: +1 301-398-0000

26. REMARKS
World Wide #: DO-ASTRAZENECA-202506CAM025155DO
Study ID: PSP.-23269
Case References: DO-AstraZeneca-CH-00901267A

24b. MFR CONTROL NO.
202506CAM025155DO

24c. DATE RECEIVED BY MANUFACTURER
30-JUN-2025

24d. REPORT SOURCE
☒ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL ☐ OTHER:

DATE OF THIS REPORT
03-JUL-2025

25a. REPORT TYPE
☒ INITIAL ☐ FOLLOWUP:

25b. NAME AND ADDRESS OF REPORTER
NAME AND ADDRESS WITHHELD.

NAME AND ADDRESS WITHHELD.

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Case Description: A solicited report has been received from a consumer in Patient Support Program, concerning a male patient (age not provided).

No medical history was reported. No concomitant products were reported.

On an unknown date, the patient started treatment with Tagrisso (osimertinib) 80 milligram qd, Oral use for lung cancer.

It was unknown if any action was taken with Tagrisso (osimertinib).

The patient died (preferred term: Death) on an unspecified date.

The patient died on an unknown date. It was not known whether an autopsy was performed. The cause of death was death.

The event was considered serious due to seriousness criteria of Death.

The reporter did not assess causality for death.
The company physician did not consider that there was a reasonable possibility of a causal relationship between Tagrisso and the following event: death.